Funding

Mitralign raises $40M

116 Views

What does Mitralign do?

Mitralign, is an innovative developer of direct transcatheter mitral and tricuspid valve repair solutions. The company focuses on developing catheter based tech for percutaneous treatments of functional mitral regurgitation. This company is venture backed privately held firm. Its novel system emulates surgical annuloplasty as it delivers surgical implants through a catheter into the mitral annulus. The implants are then cinched together, reducing the size of valve opening and the mitral valve annulus.

How much Mitralign was funded?

Mitralign raised $39.8M in Series E on May 17, 2016.

Previous funding

  • $3.5M in Series A on May 10, 2004 from Accelerated Technologies Partners, ABN AMRO Private Equity, Oxford Bioscience Partners and Giza Venture Capital.
  • $6.7M in undisclosed on June 8, 2005 from ABN AMRO Private Equity, Accelerated Technologies Partners, Giza Venture Capital and Oxford Bioscience Partners
  • $3.3M in Series B on April 20, 2006 from Triathlon Medical Venture Partners
  • $13M in Series B on June 30, 2006 from Triathlon Medical Venture Partners, Giza Venture Capital, Accelerated Technologies Partners, Oxford Bioscience Partners and ABN AMRO Private Equity.
  • $24M in Series C on December 31, 2007 from Medtronic, Accelerator Technology Holdings, Oxford Bioscience Partners, Johnson & Johnson Development Corporation, Triathlon Medical Venture Partners, Palisade Capital Management, Oakwood Medical Investors and Giza Venture Capital.
  • $35M in Series D on May 16, 2012 from Johnson & Johnson Development Corporation, Oxford Bioscience Partners,Saints Capital, Medtronic, Triathlon Medical Venture Partners and Forbion Capital Partners.
  • $7M on September 11, 2012
  • $1.9M in undisclosed round on October 26, 2012 from Orchestra Medical Ventures
  • $8M in undisclosed on June 20, 2014 from Saints Capital

What is next for Mitralign?

The company plans to continue growing its platform by pursuing CE and US regulatory approval for the Trialign system commercialization along with their preparation for commercial launch in Europe of their MPAS- Mitralign Percutaneous Annuloplasty System. The funding will be used for accelerating clinical trials in Europe and US.

More about Mitralign
The company was founded by Rick Geoffrion. It has its headquarters in Tewksbury, MA. The company is funded by top venture capitalists and 2 major cardiovascular device companies.

 

Related Posts